Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the ...

The study, published in the journal Nature, showed the jabs provided an immunity boost that helped extend survival for ...

Cancer patients who got an mRNA COVID vaccine within a few months of their immunotherapy lived longer than those who did not, health records show.

A senior biosecurity adviser at the U.S. Department of Health and Human Services, who has made several critical statements ...

The study, published in the journal Nature, showed the jabs provided an immunity boost that helped extend survival for certain skin and lung cancers.

Researchers found that COVID-19 mRNA vaccines significantly increased survival in lung and skin cancer patients undergoing ...

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.

ATLANTA — Moderna’s respiratory syncytial virus vaccine is safe and effective for adults who have received a solid organ ...

Moderna’s market value has fallen by more than 90% — $185 billion, or a full Sony — from its 2021 peak to around $10 billion ...

The Senate Homeland Security Subcommittee held a powerful hearing, 'Voices of the Vaccine-Injured,' where victims of alleged mRNA COVID vaccine injuries shared their emotional stories. Among the key ...

Cells contain a blueprint in the form of DNA that dictates what they can make. This blueprint is converted into a message ...

Thank you, operator. Good morning and good afternoon, everybody, and thank you for joining BioNTech's Third Quarter 2025 Earnings Call. As a reminder, the slides we'll use during the call and the ...